Furthermore, effective PD‐L1 blockade relies on functional antigen presentation on the tumor cell surface, where ~ 40% of patients with ccRCC have downregulated expression of the required human leukocyte antigen class I (HLA‐I) [9, 11]. Here, CD274 is linked to neoplasm.